Abstract
Remdesivir is a direct‐acting nucleoside RNA polymerase inhibitor with activity against the novel severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) virus used in the treatment of coronavirus disease 2019 (COVID‐19) pneumonia. Here, we present two cases of suspected remdesivir‐associated acute liver failure (ALF) in which the liver failure improved after continuous infusion acetylcysteine and withdrawal of remdesivir. Both patients had significant increases in transaminases between day 3 and day 10 of remdesivir therapy accompanied by coagulopathy and encephalopathy. After initiation of continuous infusion acetylcysteine, the transaminases of both patients rapidly improved. Ultimately, one patient fully recovered while the other died of suspected septic shock. Due to its novel nature and only recent widespread use, there are very little data on the risk of ALF from remdesivir. Additionally, the data for the use of acetylcysteine to manage non‐acetaminophen‐induced ALF are limited. It is important to consider the risk of remdesivir‐associated ALF when weighing the risk versus benefits of use, and acetylcysteine may have a role in its management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
